

## Breakthrough order for Micromuscle

*Linköping company Micromuscle AB has concluded a joint development agreement with a major international medical device company.*

The agreement is worth up to SEK 5 million (670,000 US dollars or 540,000 euros) during an initial development phase. Subsequently it is anticipated that the agreement will lead to royalty income from sales of hundreds of thousands of units a year. The partner, an international medical device company based in the USA, is among the top five in its segment.

Micromuscle is tasked with developing a new function for one of the US company's products. This new function, based on Micromuscle's technology and patents in the field of electro-active polymers (EAPs), will open up exciting new segments of the market.

"The agreement confirms that there is commercial confidence in our technology and in us as a company," says Micromuscle CEO Gert Kindgren. "The agreement is a follow-up to a successful technology evaluation project which has now taken more tangible shape. It also

justifies our resolve not to depart from our business model and to focus our sales work on a specific segment. This is exactly the kind of development a small technology company like ours always dreams of. It goes without saying that we're absolutely delighted and tremendously enthusiastic about the challenges that lie ahead."

For further information, please contact:  
Gert Kindgren, CEO Micromuscle  
tel. +46 705-66 56 55  
e-mail [gert.kindgren@micromuscle.com](mailto:gert.kindgren@micromuscle.com)  
[www.micromuscle.com](http://www.micromuscle.com)

## Philips and Siemens invest in new R&D resources at CMIV in Linköping


*The Center for Medical Image Science and Visualization (CMIV) is a multidisciplinary research centre set up jointly by Linköping University, Östergötland County Council and Sectra AB.*

As part of its mission to develop new methods and tools for image analysis and visualisation for use in health care and medical research, the unit undertakes world-class research into various fields of medicine and medical technology. Virtual autopsies, graphic coronary artery examinations, binocular stereopsis during brain surgery and the evaluation of cardiac function are just a few examples of the 3D medical visualisation technologies that the centre is currently developing.

Around 70 researchers and almost 20 postgraduate students are linked to CMIV, complemented by a steady stream of students who choose to gain their vocational experience here. The ratio between medical and technical staff is around 50/50, and almost all projects are multidisciplinary. The three priority areas are the brain, the heart and the blood vessels. The centre's technical equipment includes a CT scanner from Siemens and a brand new MRI scanner from Philips, wholly owned by the university. There is also research and development into functional magnetic resonance tomography (MRT) and ultrasound scanning. The centre is growing rapidly and has entered into extensive research collaborations with a number of companies. Besides local players Sectra and ContextVision, industrial partners include Philips, Siemens and Schering.

Source: [www.cmiv.liu.se](http://www.cmiv.liu.se)

For further information, please contact: Anders Persson tel. +46 13-22 89 06  
e-mail [anders.persson@cmiv.liu.se](mailto:anders.persson@cmiv.liu.se), [www.cmiv.liu.se](http://www.cmiv.liu.se)



Scan from computed tomography

## New biosensor developed by BioChromix in Linköping

*BioChromix AB is one of the latest spin-offs from the Department of Biomolecular and Organic Electronics at Linköping University.*


The company was founded when postgraduates Peter Åsberg, a biochemist, and Peter Nilsson, a technical biologist, put their heads together and combined a polymer solution with biomolecules. The result was a biosensor that detects and uses a colour-coding system to signal interactions in biomolecules (proteins, DNA, RNA and peptides).

The sensor, dubbed Apolygon, has a wide range of potential applications in the detection of misfolded proteins. It can be used both for the diagnosis of diseases caused by these proteins (such as mad cow disease, Creutzfeldt-Jakob's and Alzheimer's) and in the quality control of protein-based drugs. Production of the sensor is straightforward and is performed using the department's own laboratory equipment by two part-time employees.

BioChromix is currently in contact with several major Scandinavian drug companies and has entered into collaboration with instrument company AlphaHelix in Uppsala, where the sensor is being tested as a component in AlphaHelix's miniature pipettes to deliver exact dosages of small amounts of solvents. The market for traditional biosensors is tough with competition from several strong American and Canadian companies. Nevertheless, Åsberg and Nilsson believe there is still great potential for the type of biosensor developed by BioChromix.

Source: [www.nyteknik.se](http://www.nyteknik.se)

For further information, please see [www.biochromix.com](http://www.biochromix.com) or contact Peter Åsberg [peter.asberg@biochromix.com](mailto:peter.asberg@biochromix.com) tel. +46 709-49 17 21



*Amyloid Beta Apolygon*

## Strong growth and increased demand at Berzelius Clinical Research Center

*Berzelius Clinical Research Center AB (BCRC) in Linköping is growing rapidly with several new contracts and customers from the international pharmaceutical industry.*

As a result, BCRC needs to recruit more research nurses and expand its premises. In February it also opened a new polyclinic for day-patients, and a further 150 square metres of space has been rented at Berzelius Science Park.

BCRC works closely with the deve-

lopment departments of pharmaceutical and biotech companies and is one of Scandinavia's leading clinics for phase I and II clinical studies. These early studies currently account for the bulk of BCRC's income.

Regular quality reviews by users are part and parcel of daily life for BCRC. Four major inspections and audits were successfully carried out at the centre during the first few months of this year. In addition to audits by international

drug companies, the Swedish Medical Products Agency carried out a two-day inspection in March. The inspectors' conclusion? "BCRC is doing a great job – keep it up!"

Take a virtual tour of the centre at [www.bcrc.se](http://www.bcrc.se).

For further information, please contact: Stig Blom, tel. +46 13-473 26 30, e-mail [stig.blom@bcrc.se](mailto:stig.blom@bcrc.se), [www.bcrc.se](http://www.bcrc.se)